[go: up one dir, main page]

CO5700782A2 - Derivados de quinuckidina que se enlazan con los receptores muscarinicos m3 - Google Patents

Derivados de quinuckidina que se enlazan con los receptores muscarinicos m3

Info

Publication number
CO5700782A2
CO5700782A2 CO05112195A CO05112195A CO5700782A2 CO 5700782 A2 CO5700782 A2 CO 5700782A2 CO 05112195 A CO05112195 A CO 05112195A CO 05112195 A CO05112195 A CO 05112195A CO 5700782 A2 CO5700782 A2 CO 5700782A2
Authority
CO
Colombia
Prior art keywords
carbon atoms
alkyl
group
nitrogen
optionally substituted
Prior art date
Application number
CO05112195A
Other languages
English (en)
Inventor
Stephen Paul Collingwood
Brian Cox
Urs Baettig
Gurdip Bhalay
Nicholas James Devereux
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33420896&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5700782(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0324887A external-priority patent/GB0324887D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO5700782A2 publication Critical patent/CO5700782A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

1.- Un compuesto de la fórmula I: en forma de sal o zwiteriónica, en donde:R1 y R2 son cada uno independientemente un grupo carbocíclico de 3 a 15 átomos de carbono, o un grupo heterocícIico de 4 a 12 miembros que tiene cuando menos un heteroátomo del anillo seleccionado a partir de nitrógeno, oxígeno, y azufre,o -CR1R2R3 forman juntos un grupo de la fórmula: en donde R es un enlace, -O-, -S-, -CH2-, -CH=CH-, -CH2-CH2-, ó - N(CH3)-; R2 es hidrógeno, halógeno, hidroxilo, alcoxilo de 1 a 8 átomos de carbono, o alquilo de 1 a 8 átomos de carbono opcionalmente sustituido por hidroxilo; R4 es alquilo de 1 a 8 átomos de carbono sustituido por -NHR5, -NR5-CO-R6 , -NR5-CO-NH-R7, -NR5-SO2-R8, -CO-NR9R10, -OR11, -O-CO-NHR12, -O-CO-R13, ó -CO-O-R14, o R4 es alquinilo de 3 a 10 átomos de carbono opcionalmente sustituido por un grupo carbocíclico de 3 a 15 átomos de carbono, o un grupo heterocíclico de 4 a 12 miembros que tiene cuando menos un heteroátomo del anillo seleccionado a partir de nitrógeno, oxígeno, y azufre; R5 es hidrógeno o alquilo de 1 a 8 átomos de carbono; R6 es alquilo de 1 a 8 átomos de carbono, alquenilo de 2 a 8 átomos de carbono, alquinilo de 2 a 10 átomos de carbono, o alcoxilo de 1 a 8 átomos de carbono, en cada caso opcionalmente sustituidos por un grupo carbocíclico de 3 a 15 átomos de carbono, o un grupo heterocíclico de 4 a 12 miembros que tiene cuando menos un heteroátomo del anillo seleccionado a partir de nitrógeno, ...
CO05112195A 2003-05-02 2005-11-03 Derivados de quinuckidina que se enlazan con los receptores muscarinicos m3 CO5700782A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0310232 2003-05-02
GB0324887A GB0324887D0 (en) 2003-10-24 2003-10-24 Organic compounds

Publications (1)

Publication Number Publication Date
CO5700782A2 true CO5700782A2 (es) 2006-11-30

Family

ID=33420896

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05112195A CO5700782A2 (es) 2003-05-02 2005-11-03 Derivados de quinuckidina que se enlazan con los receptores muscarinicos m3

Country Status (31)

Country Link
US (2) US20070060563A1 (es)
EP (1) EP1631569B1 (es)
JP (1) JP4416786B2 (es)
KR (1) KR100896544B1 (es)
AR (1) AR044134A1 (es)
AT (1) ATE440840T1 (es)
AU (1) AU2004234069B2 (es)
BR (1) BRPI0410238A (es)
CA (1) CA2523436C (es)
CL (1) CL2004000918A1 (es)
CO (1) CO5700782A2 (es)
CY (1) CY1109655T1 (es)
DE (1) DE602004022805D1 (es)
DK (1) DK1631569T3 (es)
EC (1) ECSP056134A (es)
ES (1) ES2331185T3 (es)
HR (1) HRP20050933A2 (es)
IL (1) IL171591A (es)
IS (1) IS2746B (es)
MA (1) MA27775A1 (es)
MX (1) MXPA05011739A (es)
MY (1) MY142652A (es)
NO (1) NO20055688L (es)
NZ (1) NZ542995A (es)
PE (1) PE20050465A1 (es)
PL (1) PL1631569T3 (es)
PT (1) PT1631569E (es)
RU (1) RU2363700C2 (es)
SI (1) SI1631569T1 (es)
TW (1) TWI340139B (es)
WO (1) WO2004096800A2 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2239546B1 (es) * 2004-03-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos esteres de quinuclidina cuaternizados.
GB0410712D0 (en) 2004-05-13 2004-06-16 Novartis Ag Organic compounds
GB0424284D0 (en) * 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0428416D0 (en) 2004-12-24 2005-02-02 Novartis Ag Organic compounds
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
EP1900737A1 (en) * 2006-08-31 2008-03-19 Novartis AG Polymorph of (R)-3-(2-hydroxy-2,2-diphenyl-acetoxy)-1-(isoxazol-3-ylcarbamoyl-methyl)-1-azonia-bicyclo-[2.2.2]octane bromide
EP1894568A1 (en) * 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
EP2121137B1 (en) * 2006-12-19 2012-04-25 AstraZeneca AB Quinuclidinol derivatives as muscarinic receptor antagonists
EP1950196A1 (de) * 2007-01-29 2008-07-30 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Herstellung von Ammoniumhexafluorophosphaten
BRPI0816219B8 (pt) * 2007-09-07 2021-05-25 Theravance Biopharma R&D Ip Llc compostos contendo guanidina úteis como antagonistas de receptor muscarínico, composição farmacêutica e uso
EP2222637A1 (en) * 2007-12-14 2010-09-01 Theravance, Inc. Amidine-containing compounds useful as muscarinic receptor antagonists
JP5584138B2 (ja) 2008-01-11 2014-09-03 ノバルティス アーゲー キナーゼ阻害剤としてのピリミジン類
US8329729B2 (en) * 2008-05-13 2012-12-11 Astrazeneca Ab Quinuclidine derivatives as muscarinic M3 receptor antagonists
RU2010147881A (ru) * 2008-05-13 2012-06-20 Астразенека Аб (Se) ФАРМАЦЕВТИЧЕСКИЙ ПРОДУКТ, СОДЕРЖАЩИЙ АНТАГОНИСТ МУСКАРИНОВОГО РЕЦЕПТОРА И АГОНИСТ β2-АДРЕНОРЕЦЕПТОРА
GB0808709D0 (en) * 2008-05-13 2008-06-18 Astrazeneca Ab New combination 295
US20090326004A1 (en) 2008-06-03 2009-12-31 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
WO2009153536A1 (en) * 2008-06-17 2009-12-23 Argenta Discovery Limited 1-aza-bicyclo [2.2.2] octane derivatives useful as muscarinic receptor antagonists
GB0811100D0 (en) * 2008-06-17 2008-07-23 Astrazeneca Ab New combination
BR112012032332A2 (pt) * 2010-06-22 2016-11-08 Chiesi Farma Spa composto, uso de um composto, composição farmacêutica, combinação de um composto e dispositivo
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
CA2828219A1 (en) 2011-02-25 2012-08-30 Irm Llc Pyrazolo [1,5-a] pyridines as trk inhibitors
JP2011195593A (ja) * 2011-06-30 2011-10-06 Astrazeneca Ab ムスカリンm3受容体アンタゴニストとしてのキヌクリジン誘導体
BR112014013179A2 (pt) * 2011-12-30 2017-06-13 Chiesi Farm Spa compostos, combinação de um composto, composição farmacêutica e usos de um composto
CA2871926A1 (en) 2012-05-03 2013-11-07 Saint Louis College Of Pharmacy Compositions and methods for increasing neurotrophic peptides
TWI647227B (zh) * 2013-02-28 2019-01-11 日商安斯泰來製藥股份有限公司 2-醯胺噻唑衍生物或其鹽
CZ306791B6 (cs) 2013-10-29 2017-07-12 Zentiva, K.S. Průmyslově využitelný způsob přípravy aklidinium bromidu o vysoké čistotě
PT108370B (pt) * 2015-03-30 2018-10-25 Hovione Farm S A Processo de preparação de brometo de aclidínio
PL3111978T3 (pl) 2015-07-03 2022-01-24 Novartis Ag Inhalator przystosowany do odczytu informacji przechowywanych w środkach przechowywania danych pojemnika

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1219606A (en) * 1968-07-15 1971-01-20 Rech S Et D Applic Scient Soge Quinuclidinol derivatives and preparation thereof
DK534178A (da) * 1977-12-16 1979-06-17 Interx Research Corp Anticholinerge midler med sektrtionshaemmende virkning
IT1230881B (it) * 1989-06-20 1991-11-08 Angeli Inst Spa Derivati del r(-) 3-chinuclidinolo
ES2165768B1 (es) * 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
CA2415468A1 (en) * 2000-07-11 2003-01-10 Yoshio Ogino Ester derivatives
KR100869721B1 (ko) * 2000-12-28 2008-11-21 알미랄 에이쥐 신규한 퀴누클리딘 유도체 및 그를 함유한 의약 조성물
US7452904B2 (en) * 2001-12-20 2008-11-18 Chiesi Farmaceutici S.P.A. 1-alkyl-1-azoniabicyclo' 2.2.2 octane carbamate derivatives and their use as muscarinic receptor antagonists
GB0424284D0 (en) * 2004-11-02 2004-12-01 Novartis Ag Organic compounds
EP1900737A1 (en) * 2006-08-31 2008-03-19 Novartis AG Polymorph of (R)-3-(2-hydroxy-2,2-diphenyl-acetoxy)-1-(isoxazol-3-ylcarbamoyl-methyl)-1-azonia-bicyclo-[2.2.2]octane bromide

Also Published As

Publication number Publication date
AR044134A1 (es) 2005-08-24
US20100041887A1 (en) 2010-02-18
PE20050465A1 (es) 2005-07-18
NZ542995A (en) 2009-02-28
MXPA05011739A (es) 2006-01-26
CL2004000918A1 (es) 2005-02-11
NO20055688D0 (no) 2005-12-01
JP2006525267A (ja) 2006-11-09
KR20060015572A (ko) 2006-02-17
PL1631569T3 (pl) 2010-02-26
JP4416786B2 (ja) 2010-02-17
NO20055688L (no) 2006-01-09
US20070060563A1 (en) 2007-03-15
RU2005137360A (ru) 2006-07-27
EP1631569A2 (en) 2006-03-08
ES2331185T3 (es) 2009-12-23
KR100896544B1 (ko) 2009-05-07
BRPI0410238A (pt) 2006-05-16
EP1631569B1 (en) 2009-08-26
IL171591A (en) 2010-11-30
MA27775A1 (fr) 2006-02-01
IS8158A (is) 2005-11-30
RU2363700C2 (ru) 2009-08-10
MY142652A (en) 2010-12-15
AU2004234069B2 (en) 2008-02-21
DE602004022805D1 (de) 2009-10-08
WO2004096800A3 (en) 2005-01-06
PT1631569E (pt) 2009-11-26
WO2004096800A2 (en) 2004-11-11
HRP20050933A2 (en) 2006-12-31
ATE440840T1 (de) 2009-09-15
IS2746B (is) 2011-08-15
SI1631569T1 (sl) 2010-01-29
DK1631569T3 (da) 2009-11-23
CA2523436A1 (en) 2004-11-11
US8168654B2 (en) 2012-05-01
CA2523436C (en) 2011-11-01
HK1087704A1 (en) 2006-10-20
CY1109655T1 (el) 2014-08-13
TWI340139B (en) 2011-04-11
ECSP056134A (es) 2006-04-19
TW200505920A (en) 2005-02-16
AU2004234069A1 (en) 2004-11-11

Similar Documents

Publication Publication Date Title
CO5700782A2 (es) Derivados de quinuckidina que se enlazan con los receptores muscarinicos m3
AR048669A1 (es) Derivados biciclicos de bisamida
NI201000018A (es) Derivado de oxopirazina y herbicida
CO6321166A2 (es) Compuestos de pirrol
ES2452299T3 (es) Compuestos heterocíclicos fungicidas
CO6140056A2 (es) Compuestos amino -5-4(difluorometoxi)fenil sustituido-5-fenilimidazolona como inhibidores de beta -secretasa
AR047533A1 (es) Proceso para preparar carboxamidas 2-aminotiazol-5-aromaticas como inhibidores de la quinasa
AR077440A1 (es) Bencenosulfonamidas como bloqueadores de canales de calcio y composiciones farmaceuticas
CO5721002A2 (es) Derivados de acido 3-(4-benciloxifenil) propanoico
NO20071642L (no) N-Benzensulfonylsubstituerte anilino-pyrimidinanaloger
ES2662397T3 (es) Inhibidores de la quinasa reguladora de la señal de apoptosis
EA200800285A1 (ru) Новые производные 2,4-дианилинопиримидинов, их получение, лекарственные средства, фармацевтические композиции, содержащие указанные производные, и их применение, в частности, в качестве ингибиторов ikk
DK1200426T3 (da) Substituerede thien-3-yl-sulfonylamino(thio)carbonyl-tiazolin(thi)oner
AR057987A1 (es) Compuestos agonistas de cb1 (receptor cannabinoide)
AR058554A1 (es) Compuestos heterociclicos nitrogenados de 6 miembros sustituidos, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades mediadas por mglur5.
CO6220949A2 (es) Derivados pirazolicos como inhibidores de la 11 beta -hsd1
CO5060482A1 (es) Derivados terapeuticos de biarilo
CY1113657T1 (el) Νεα παραγωγα βενζοφαινονης ή αλατα αυτων
CO4950537A1 (es) Benzoteinas novedosas que tienen actividad como inhibidores del transporte del acido biliar ilear y consumo de taurocola to
CO6150144A2 (es) Inhibidores de proteina tirosina fosfatasa humana y metodos de uso
AR061369A1 (es) Derivados de pirimidina y composiciones farmaceuticas que los comprenden
CO5580815A2 (es) Derivados de adamantana, procesos para su preparacion y composiciones farmaceuticas que los contienen
NZ774547A (en) 7h-purino[8,9-b][1,3]oxazole-4-amine derivatives and analogues as aryl hydrocarbon receptor antagonists
AR040626A1 (es) Derivados de quinolina utiles como ligandos del receptor del neuropeptido y (npy)
CO5031250A1 (es) Compuesto farmaceutico

Legal Events

Date Code Title Description
FG Application granted
FD Application lapsed